MYUNGMOON Pharm co.,Ltd reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 2,589.15 million compared to KRW 2,836.73 million a year ago. Net loss was KRW 136.94 million compared to net income of KRW 2,176.02 million a year ago. Basic loss per share from continuing operations was KRW 4 compared to basic earnings per share from continuing operations of KRW 64 a year ago. Basic loss per share was KRW 4 compared to basic earnings per share of KRW 64 a year ago.
For the six months, sales was KRW 4,225.82 million compared to KRW 4,163.25 million a year ago. Net income was KRW 445.74 million compared to KRW 3,141.31 million a year ago. Basic earnings per share from continuing operations was KRW 13 compared to KRW 93 a year ago. Basic earnings per share was KRW 13 compared to KRW 93 a year ago.